$SGMO
Sangamo Therapeutics Inc

2013 Q4 Form 10-Q Financial Statement

#000119312513425338 Filed on November 04, 2013

View on sec.gov

Income Statement

Concept 2013 Q4 2013 Q3 2012 Q3
Revenue $6.869M $5.707M $4.907M
YoY Change -23.09% 16.3% 163.82%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $4.110M $3.160M $3.140M
YoY Change 36.09% 0.64% -12.53%
% of Gross Profit
Research & Development $10.78M $8.703M $7.570M
YoY Change 16.16% 14.97% -3.44%
% of Gross Profit
Depreciation & Amortization $200.0K $100.0K $200.0K
YoY Change 0.0% -50.0% 0.0%
% of Gross Profit
Operating Expenses $15.04M $11.87M $10.71M
YoY Change 22.3% 10.8% -6.31%
Operating Profit -$6.159M -$5.802M
YoY Change 6.15%
Interest Expense $30.00K $10.00K $10.00K
YoY Change -127.27% 0.0% -50.0%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$8.140M -$6.150M -$5.790M
YoY Change 133.91% 6.22% -39.37%
Income Tax $0.00 $0.00 $0.00
% Of Pretax Income
Net Earnings -$8.144M -$6.145M -$5.790M
YoY Change 134.16% 6.13% -39.37%
Net Earnings / Revenue -118.56% -107.67% -117.99%
Basic Earnings Per Share
Diluted Earnings Per Share -$131.6K -$112.2K -$109.7K
COMMON SHARES
Basic Shares Outstanding 61.80M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2013 Q4 2013 Q3 2012 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $138.4M $120.2M $57.90M
YoY Change 45.75% 107.6% -31.4%
Cash & Equivalents $10.19M $80.31M $13.72M
Short-Term Investments $128.2M $39.90M $44.20M
Other Short-Term Assets $191.0K $149.0K $700.0K
YoY Change -5.91% -78.71% 16.67%
Inventory
Prepaid Expenses $457.0K $684.0K
Receivables $3.155M $4.880M $3.500M
Other Receivables $300.0K $200.0K $300.0K
Total Short-Term Assets $97.27M $126.1M $62.40M
YoY Change 42.29% 102.15% -28.03%
LONG-TERM ASSETS
Property, Plant & Equipment $1.406M $1.494M $1.500M
YoY Change -8.88% -0.4% -6.25%
Goodwill $1.585M
YoY Change
Intangibles
YoY Change
Long-Term Investments $38.70M $12.70M $17.90M
YoY Change 207.14% -29.05%
Other Assets $40.00K $0.00 $0.00
YoY Change
Total Long-Term Assets $43.56M $14.22M $19.40M
YoY Change 207.48% -26.69% 1112.5%
TOTAL ASSETS
Total Short-Term Assets $97.27M $126.1M $62.40M
Total Long-Term Assets $43.56M $14.22M $19.40M
Total Assets $140.8M $140.4M $81.80M
YoY Change 70.64% 71.6% -7.36%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $3.022M $2.700M $1.700M
YoY Change -0.79% 58.82% -32.0%
Accrued Expenses $3.700M $2.000M $1.800M
YoY Change 37.04% 11.11% 28.57%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $10.13M $7.004M $6.000M
YoY Change 15.26% 16.73% 46.34%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $8.200M $7.200M $9.400M
YoY Change -6.82% -23.4%
Total Long-Term Liabilities $8.200M $7.200M $9.400M
YoY Change -6.82% -23.4%
TOTAL LIABILITIES
Total Short-Term Liabilities $10.13M $7.004M $6.000M
Total Long-Term Liabilities $8.200M $7.200M $9.400M
Total Liabilities $19.13M $14.23M $15.40M
YoY Change 8.45% -7.63% 275.61%
SHAREHOLDERS EQUITY
Retained Earnings -$302.1M -$294.0M
YoY Change 9.66%
Common Stock $423.8M $614.0K
YoY Change 79717.51%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $121.7M $126.1M $66.40M
YoY Change
Total Liabilities & Shareholders Equity $140.8M $140.4M $81.80M
YoY Change 70.64% 71.6% -7.36%

Cashflow Statement

Concept 2013 Q4 2013 Q3 2012 Q3
OPERATING ACTIVITIES
Net Income -$8.144M -$6.145M -$5.790M
YoY Change 134.16% 6.13% -39.37%
Depreciation, Depletion And Amortization $200.0K $100.0K $200.0K
YoY Change 0.0% -50.0% 0.0%
Cash From Operating Activities -$1.700M -$4.500M -$5.200M
YoY Change -950.0% -13.46% -20.0%
INVESTING ACTIVITIES
Capital Expenditures $0.00 -$100.0K -$100.0K
YoY Change -100.0% 0.0% -50.0%
Acquisitions
YoY Change
Other Investing Activities -$68.90M $1.300M $0.00
YoY Change -1031.08% -100.0%
Cash From Investing Activities -$68.90M $1.300M -$200.0K
YoY Change -1070.42% -750.0% -101.02%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 500.0K 71.50M 500.0K
YoY Change -28.57% 14200.0% 400.0%
NET CHANGE
Cash From Operating Activities -1.700M -4.500M -5.200M
Cash From Investing Activities -68.90M 1.300M -200.0K
Cash From Financing Activities 500.0K 71.50M 500.0K
Net Change In Cash -70.10M 68.30M -4.900M
YoY Change -976.25% -1493.88% -137.12%
FREE CASH FLOW
Cash From Operating Activities -$1.700M -$4.500M -$5.200M
Capital Expenditures $0.00 -$100.0K -$100.0K
Free Cash Flow -$1.700M -$4.400M -$5.100M
YoY Change -440.0% -13.73% -19.05%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2013Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
61797202 shares
CY2012Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
13724000
CY2013Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
61420655 shares
CY2013Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
61420655 shares
CY2013Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
80000000 shares
CY2013Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2013Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
419490000
CY2013Q3 us-gaap Liabilities Current
LiabilitiesCurrent
7004000
CY2013Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
26000
CY2013Q3 us-gaap Stockholders Equity
StockholdersEquity
126141000
CY2013Q3 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
2039000
CY2013Q3 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
2665000
CY2013Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-293989000
CY2013Q3 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
2300000
CY2013Q3 us-gaap Common Stock Value
CommonStockValue
614000
CY2013Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
140366000
CY2013Q3 us-gaap Liabilities
Liabilities
14225000
CY2013Q3 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
7221000
CY2013Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2013Q3 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
39913000
CY2013Q3 us-gaap Assets Current
AssetsCurrent
126143000
CY2013Q3 us-gaap Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
62335000
CY2013Q3 us-gaap Marketable Securities Noncurrent
MarketableSecuritiesNoncurrent
12690000
CY2013Q3 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
684000
CY2013Q3 us-gaap Assets
Assets
140366000
CY2013Q3 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
62361000
CY2012Q4 us-gaap Common Stock Value
CommonStockValue
531000
CY2012Q4 us-gaap Marketable Securities Noncurrent
MarketableSecuritiesNoncurrent
12584000
CY2012Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
296000
CY2013Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
80309000
CY2013Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
4880000
CY2013Q3 us-gaap Available For Sale Securities
AvailableForSaleSecurities
62361000
CY2013Q3 us-gaap Other Assets
OtherAssets
39000
CY2013Q3 us-gaap Other Assets Current
OtherAssetsCurrent
149000
CY2013Q3 us-gaap Interest Receivable Current
InterestReceivableCurrent
208000
CY2013Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1494000
CY2013Q3 sgmo Investments Maturity Dates Available For Sale Securities
InvestmentsMaturityDatesAvailableForSaleSecurities
P1Y
CY2013Q3 sgmo Available For Sale Securities Gross Unrealized Loss Accumulated In Investments
AvailableForSaleSecuritiesGrossUnrealizedLossAccumulatedInInvestments
CY2013Q3 sgmo Available For Sale Securities Gross Unrealized Gains Accumulated In Investments
AvailableForSaleSecuritiesGrossUnrealizedGainsAccumulatedInInvestments
26000
CY2011Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
16766000
CY2012Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
53058525 shares
CY2012Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
53058525 shares
CY2012Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
80000000 shares
CY2012Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2012Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
339848000
CY2012Q4 us-gaap Liabilities Current
LiabilitiesCurrent
8790000
CY2012Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
26000
CY2012Q4 us-gaap Stockholders Equity
StockholdersEquity
64896000
CY2012Q4 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
2473000
CY2012Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
4013000
CY2012Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-275509000
CY2012Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
2304000
CY2012Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
82533000
CY2012Q4 us-gaap Liabilities
Liabilities
17637000
CY2012Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
8847000
CY2012Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2012Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
41868000
CY2012Q4 us-gaap Assets Current
AssetsCurrent
68365000
CY2012Q4 us-gaap Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
73262000
CY2012Q4 us-gaap Assets
Assets
82533000
CY2012Q4 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
73288000
CY2012Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
21679000
CY2012Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
4129000
CY2012Q4 us-gaap Available For Sale Securities
AvailableForSaleSecurities
73288000
CY2012Q4 us-gaap Other Assets
OtherAssets
41000
CY2012Q4 us-gaap Other Assets Current
OtherAssetsCurrent
203000
CY2012Q4 us-gaap Interest Receivable Current
InterestReceivableCurrent
190000
CY2012Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1543000
CY2012Q4 sgmo Available For Sale Securities Gross Unrealized Loss Accumulated In Investments
AvailableForSaleSecuritiesGrossUnrealizedLossAccumulatedInInvestments
CY2012Q4 sgmo Available For Sale Securities Gross Unrealized Gains Accumulated In Investments
AvailableForSaleSecuritiesGrossUnrealizedGainsAccumulatedInInvestments
26000
dei Entity Registrant Name
EntityRegistrantName
SANGAMO BIOSCIENCES INC
dei Amendment Flag
AmendmentFlag
false
dei Entity Filer Category
EntityFilerCategory
Accelerated Filer
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2013
dei Document Type
DocumentType
10-Q
dei Document Period End Date
DocumentPeriodEndDate
2013-09-30
dei Entity Central Index Key
EntityCentralIndexKey
0001001233
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
54013000 shares
us-gaap Operating Income Loss
OperatingIncomeLoss
-18532000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-17825000
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.34
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
7853936 shares
us-gaap Use Of Estimates
UseOfEstimates
<div> <p style="MARGIN-TOP: 18pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; MARGIN-LEFT: 2%; FONT-SIZE: 10pt"> <b><i>Use of Estimates and Classifications</i></b></p> <p style="MARGIN-TOP: 6pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"> The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the amounts reported in the financial statements and the accompanying notes. On an ongoing basis, management evaluates its estimates, including critical accounting policies or estimates related to revenue recognition, clinical trial accruals, and stock-based compensation. Estimates are based on historical experience and on various other market specific and other relevant assumptions that the Company believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ from those estimates.</p> </div>
us-gaap Revenues
Revenues
17264000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
387000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-18480000
us-gaap Investment Income Interest
InvestmentIncomeInterest
52000
us-gaap Revenue From Grants
RevenueFromGrants
2199000
us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
37161000
us-gaap Increase Decrease In Accrued Interest Receivable Net
IncreaseDecreaseInAccruedInterestReceivableNet
18000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
696000
us-gaap Net Income Loss
NetIncomeLoss
-18480000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
395000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-434000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
9595000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
75627000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-1630000
us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
-1348000
us-gaap Share Based Compensation
ShareBasedCompensation
4098000
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
58630000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
6135000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
828000
us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
69492000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
26201000
us-gaap Proceeds From Maturities Prepayments And Calls Of Longterm Investments
ProceedsFromMaturitiesPrepaymentsAndCallsOfLongtermInvestments
38384000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
445000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4098000
us-gaap Operating Expenses
OperatingExpenses
35796000
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
625000
sgmo Collaboration Agreements
CollaborationAgreements
15065000
sgmo Potential Royalty Payments To Entity
PotentialRoyaltyPaymentsToEntity
Two times the amount Sangamo receives in funding under the agreement
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
52664000 shares
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-8305000
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.36
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
8075898 shares
us-gaap Revenues
Revenues
12723000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
364000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-18783000
us-gaap Investment Income Interest
InvestmentIncomeInterest
43000
us-gaap Revenue From Grants
RevenueFromGrants
3058000
us-gaap Operating Income Loss
OperatingIncomeLoss
-18829000
us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
70570000
us-gaap Increase Decrease In Accrued Interest Receivable Net
IncreaseDecreaseInAccruedInterestReceivableNet
-20000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
2585000
us-gaap Net Income Loss
NetIncomeLoss
-18786000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
363000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
3000
us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
159000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
9125000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
1041000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
11818000
CY2013Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
8703000
CY2013Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1391000
CY2013Q3 us-gaap Operating Expenses
OperatingExpenses
11866000
CY2013Q3 sgmo Collaboration Agreements
CollaborationAgreements
4825000
us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
-3770000
us-gaap Share Based Compensation
ShareBasedCompensation
4011000
CY2013Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
14000
CY2012Q3 sgmo Collaboration Agreements
CollaborationAgreements
4190000
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-3042000
CY2013Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
54786000 shares
CY2013Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.11
CY2013Q3 us-gaap Revenues
Revenues
5707000
CY2013Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-6118000
CY2013Q3 us-gaap Revenue From Grants
RevenueFromGrants
882000
CY2013Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-6159000
CY2013Q3 us-gaap Net Income Loss
NetIncomeLoss
-6145000
CY2013Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
27000
CY2013Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3163000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
1041000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
4222000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
22427000
us-gaap Proceeds From Maturities Prepayments And Calls Of Longterm Investments
ProceedsFromMaturitiesPrepaymentsAndCallsOfLongtermInvestments
75155000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
500000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4011000
us-gaap Operating Expenses
OperatingExpenses
31552000
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
692000
sgmo Collaboration Agreements
CollaborationAgreements
9665000
CY2012Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
52768000 shares
CY2012Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.11
CY2012Q3 us-gaap Revenues
Revenues
4907000
CY2012Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-5768000
CY2012Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
12000
CY2012Q3 us-gaap Revenue From Grants
RevenueFromGrants
717000
CY2012Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-5802000
CY2012Q3 us-gaap Net Income Loss
NetIncomeLoss
-5790000
CY2012Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
22000
CY2012Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3139000
CY2012Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
7570000
CY2012Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1404000
CY2012Q3 us-gaap Operating Expenses
OperatingExpenses
10709000

Files In Submission

Name View Source Status
0001193125-13-425338-index-headers.html Edgar Link pending
0001193125-13-425338-index.html Edgar Link pending
0001193125-13-425338.txt Edgar Link pending
0001193125-13-425338-xbrl.zip Edgar Link pending
d595389d10q.htm Edgar Link pending
d595389dex101.htm Edgar Link pending
d595389dex102.htm Edgar Link pending
d595389dex311.htm Edgar Link pending
d595389dex312.htm Edgar Link pending
d595389dex321.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xls Edgar Link pending
Financial_Report.xlsx Edgar Link pending
g595389g50d01.jpg Edgar Link pending
g595389g77q05.jpg Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
sgmo-20130930.xml Edgar Link completed
sgmo-20130930.xsd Edgar Link pending
sgmo-20130930_cal.xml Edgar Link unprocessable
sgmo-20130930_def.xml Edgar Link unprocessable
sgmo-20130930_lab.xml Edgar Link unprocessable
sgmo-20130930_pre.xml Edgar Link unprocessable
Show.js Edgar Link pending